Death effector domain-containing protein induces vulnerability to cell cycle inhibition in triple-negative breast cancer

Yingjia Ni, Keon R. Schmidt, Barnes A. Werner, Jenna K. Koenig, Ian H. Guldner, Patricia M. Schnepp, Xuejuan Tan, Lan Jiang, Misha Host, Longhua Sun, Erin N. Howe, Junmin Wu, Laurie E. Littlepage, Harikrishna Nakshatri, Siyuan Zhang

Research output: Contribution to journalArticle

Abstract

Lacking targetable molecular drivers, triple-negative breast cancer (TNBC) is the most clinically challenging subtype of breast cancer. In this study, we reveal that Death Effector Domain-containing DNA-binding protein (DEDD), which is overexpressed in > 60% of TNBCs, drives a mitogen-independent G1/S cell cycle transition through cytoplasm localization. The gain of cytosolic DEDD enhances cyclin D1 expression by interacting with heat shock 71 kDa protein 8 (HSC70). Concurrently, DEDD interacts with Rb family proteins and promotes their proteasome-mediated degradation. DEDD overexpression renders TNBCs vulnerable to cell cycle inhibition. Patients with TNBC have been excluded from CDK 4/6 inhibitor clinical trials due to the perceived high frequency of Rb-loss in TNBCs. Interestingly, our study demonstrated that, irrespective of Rb status, TNBCs with DEDD overexpression exhibit a DEDD-dependent vulnerability to combinatorial treatment with CDK4/6 inhibitor and EGFR inhibitor in vitro and in vivo. Thus, our study provided a rationale for the clinical application of CDK4/6 inhibitor combinatorial regimens for patients with TNBC.

Original languageEnglish (US)
Article number2860
JournalNature communications
Volume10
Issue number1
DOIs
StatePublished - Dec 1 2019

Fingerprint

Death Domain Receptor Signaling Adaptor Proteins
Triple Negative Breast Neoplasms
effectors
vulnerability
death
breast
inhibitors
Cell Cycle
cancer
Cells
proteins
Retinoblastoma Protein
cycles
Cyclin D1
DNA-Binding Proteins
Proteasome Endopeptidase Complex
Mitogens
Shock
Cytoplasm
Proteins

ASJC Scopus subject areas

  • Chemistry(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Physics and Astronomy(all)

Cite this

Ni, Y., Schmidt, K. R., Werner, B. A., Koenig, J. K., Guldner, I. H., Schnepp, P. M., ... Zhang, S. (2019). Death effector domain-containing protein induces vulnerability to cell cycle inhibition in triple-negative breast cancer. Nature communications, 10(1), [2860]. https://doi.org/10.1038/s41467-019-10743-7

Death effector domain-containing protein induces vulnerability to cell cycle inhibition in triple-negative breast cancer. / Ni, Yingjia; Schmidt, Keon R.; Werner, Barnes A.; Koenig, Jenna K.; Guldner, Ian H.; Schnepp, Patricia M.; Tan, Xuejuan; Jiang, Lan; Host, Misha; Sun, Longhua; Howe, Erin N.; Wu, Junmin; Littlepage, Laurie E.; Nakshatri, Harikrishna; Zhang, Siyuan.

In: Nature communications, Vol. 10, No. 1, 2860, 01.12.2019.

Research output: Contribution to journalArticle

Ni, Y, Schmidt, KR, Werner, BA, Koenig, JK, Guldner, IH, Schnepp, PM, Tan, X, Jiang, L, Host, M, Sun, L, Howe, EN, Wu, J, Littlepage, LE, Nakshatri, H & Zhang, S 2019, 'Death effector domain-containing protein induces vulnerability to cell cycle inhibition in triple-negative breast cancer', Nature communications, vol. 10, no. 1, 2860. https://doi.org/10.1038/s41467-019-10743-7
Ni, Yingjia ; Schmidt, Keon R. ; Werner, Barnes A. ; Koenig, Jenna K. ; Guldner, Ian H. ; Schnepp, Patricia M. ; Tan, Xuejuan ; Jiang, Lan ; Host, Misha ; Sun, Longhua ; Howe, Erin N. ; Wu, Junmin ; Littlepage, Laurie E. ; Nakshatri, Harikrishna ; Zhang, Siyuan. / Death effector domain-containing protein induces vulnerability to cell cycle inhibition in triple-negative breast cancer. In: Nature communications. 2019 ; Vol. 10, No. 1.
@article{c957f91f18a141caa7ef7f4905b38652,
title = "Death effector domain-containing protein induces vulnerability to cell cycle inhibition in triple-negative breast cancer",
abstract = "Lacking targetable molecular drivers, triple-negative breast cancer (TNBC) is the most clinically challenging subtype of breast cancer. In this study, we reveal that Death Effector Domain-containing DNA-binding protein (DEDD), which is overexpressed in > 60{\%} of TNBCs, drives a mitogen-independent G1/S cell cycle transition through cytoplasm localization. The gain of cytosolic DEDD enhances cyclin D1 expression by interacting with heat shock 71 kDa protein 8 (HSC70). Concurrently, DEDD interacts with Rb family proteins and promotes their proteasome-mediated degradation. DEDD overexpression renders TNBCs vulnerable to cell cycle inhibition. Patients with TNBC have been excluded from CDK 4/6 inhibitor clinical trials due to the perceived high frequency of Rb-loss in TNBCs. Interestingly, our study demonstrated that, irrespective of Rb status, TNBCs with DEDD overexpression exhibit a DEDD-dependent vulnerability to combinatorial treatment with CDK4/6 inhibitor and EGFR inhibitor in vitro and in vivo. Thus, our study provided a rationale for the clinical application of CDK4/6 inhibitor combinatorial regimens for patients with TNBC.",
author = "Yingjia Ni and Schmidt, {Keon R.} and Werner, {Barnes A.} and Koenig, {Jenna K.} and Guldner, {Ian H.} and Schnepp, {Patricia M.} and Xuejuan Tan and Lan Jiang and Misha Host and Longhua Sun and Howe, {Erin N.} and Junmin Wu and Littlepage, {Laurie E.} and Harikrishna Nakshatri and Siyuan Zhang",
year = "2019",
month = "12",
day = "1",
doi = "10.1038/s41467-019-10743-7",
language = "English (US)",
volume = "10",
journal = "Nature Communications",
issn = "2041-1723",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Death effector domain-containing protein induces vulnerability to cell cycle inhibition in triple-negative breast cancer

AU - Ni, Yingjia

AU - Schmidt, Keon R.

AU - Werner, Barnes A.

AU - Koenig, Jenna K.

AU - Guldner, Ian H.

AU - Schnepp, Patricia M.

AU - Tan, Xuejuan

AU - Jiang, Lan

AU - Host, Misha

AU - Sun, Longhua

AU - Howe, Erin N.

AU - Wu, Junmin

AU - Littlepage, Laurie E.

AU - Nakshatri, Harikrishna

AU - Zhang, Siyuan

PY - 2019/12/1

Y1 - 2019/12/1

N2 - Lacking targetable molecular drivers, triple-negative breast cancer (TNBC) is the most clinically challenging subtype of breast cancer. In this study, we reveal that Death Effector Domain-containing DNA-binding protein (DEDD), which is overexpressed in > 60% of TNBCs, drives a mitogen-independent G1/S cell cycle transition through cytoplasm localization. The gain of cytosolic DEDD enhances cyclin D1 expression by interacting with heat shock 71 kDa protein 8 (HSC70). Concurrently, DEDD interacts with Rb family proteins and promotes their proteasome-mediated degradation. DEDD overexpression renders TNBCs vulnerable to cell cycle inhibition. Patients with TNBC have been excluded from CDK 4/6 inhibitor clinical trials due to the perceived high frequency of Rb-loss in TNBCs. Interestingly, our study demonstrated that, irrespective of Rb status, TNBCs with DEDD overexpression exhibit a DEDD-dependent vulnerability to combinatorial treatment with CDK4/6 inhibitor and EGFR inhibitor in vitro and in vivo. Thus, our study provided a rationale for the clinical application of CDK4/6 inhibitor combinatorial regimens for patients with TNBC.

AB - Lacking targetable molecular drivers, triple-negative breast cancer (TNBC) is the most clinically challenging subtype of breast cancer. In this study, we reveal that Death Effector Domain-containing DNA-binding protein (DEDD), which is overexpressed in > 60% of TNBCs, drives a mitogen-independent G1/S cell cycle transition through cytoplasm localization. The gain of cytosolic DEDD enhances cyclin D1 expression by interacting with heat shock 71 kDa protein 8 (HSC70). Concurrently, DEDD interacts with Rb family proteins and promotes their proteasome-mediated degradation. DEDD overexpression renders TNBCs vulnerable to cell cycle inhibition. Patients with TNBC have been excluded from CDK 4/6 inhibitor clinical trials due to the perceived high frequency of Rb-loss in TNBCs. Interestingly, our study demonstrated that, irrespective of Rb status, TNBCs with DEDD overexpression exhibit a DEDD-dependent vulnerability to combinatorial treatment with CDK4/6 inhibitor and EGFR inhibitor in vitro and in vivo. Thus, our study provided a rationale for the clinical application of CDK4/6 inhibitor combinatorial regimens for patients with TNBC.

UR - http://www.scopus.com/inward/record.url?scp=85068153495&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068153495&partnerID=8YFLogxK

U2 - 10.1038/s41467-019-10743-7

DO - 10.1038/s41467-019-10743-7

M3 - Article

VL - 10

JO - Nature Communications

JF - Nature Communications

SN - 2041-1723

IS - 1

M1 - 2860

ER -